In addition, because the demonstration will operate outside the Part D benefit, the manufacturers wont be responsible for providing the manufacturer price discount on eligible GLP-1s (10% in the Part D initial benefit phase and 20% in the catastrophic phase.) While many prior section 402 demonstrations have had to conform to budget neutrality rules by the Office of Management and Budget (OMB), some demonstrations have been able to move forward without this requirement
PubMed Bock-Marquette I, Saxena A, White MD, et al
Distinct Anxiolytic Profile Anxiolytic effects distinct from benzodiazepines emerged in shock probe/burying and light/dark tests
Exendin-4, a homolog of GLP-1 acting as an agonist for the GLP-1 receptor, is a 39-amino acid peptide that was initially identified in the venomous lizard Heloderma suspectum (Runge et al., 2007)
It belongs to a class of agents known as multi-incretin receptor agonists, meaning it simultaneously targets three hormone receptors: the glucagon-like peptide-1 (GLP-1) receptor, the glucose-dependent insulinotropic polypeptide (GIP) receptor, and the glucagon receptor